GenScript's AI Drug Discovery Business Doubles, Driving 27% Revenue Surge — GenScript Biotech Corporation

Event summary

GenScript reported first-half 2026 revenue of $404.2 million, up 27.3% YoY, with adjusted net profit surging 203.3% to $62.5 million.
AI-enabled drug discovery business doubled YoY, maintaining rapid growth for three consecutive half-year periods.
Gene-to-Protein segment accounted for 66% of GenScript Life Science Group revenue, remaining the primary growth engine.
ProBio revenue increased 34.2% with new orders up 54%, while Bestzyme revenue grew 7.4% with adjusted gross profit up 14.0%.
GenScript expects continued momentum in the second half of 2026, supported by growing order base and investments in automation and capacity.

The big picture

GenScript's strong first-half 2026 results highlight the accelerating demand for AI-enabled drug discovery services, driven by the increasing scale and complexity of biopharmaceutical research. The company's integrated Gene-to-Protein platform positions it as a key player in the evolving life sciences landscape, where AI is reshaping traditional drug development workflows. With continued investments in global manufacturing capacity and automation, GenScript aims to solidify its role as a critical infrastructure partner for AI-focused biotechnology companies and pharmaceutical innovators.

What we're watching

AI Integration: How GenScript's investments in automation and digital workflows will affect its ability to support increasingly complex AI-driven drug discovery programs.
Operational Efficiency: Whether ProBio can sustain its order growth and achieve positive adjusted EBITDA by 2027 as projected.
Market Positioning: The pace at which GenScript can deepen customer relationships and strengthen its role as a critical infrastructure partner in the AI drug discovery ecosystem.